13
Mar
2025

Protagonist Delivers, BMS Bargain Hunts, and Zealand Goes Major League

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue
Dimension Hauls In $800M, Arrowhead Nails Triglycerides, Tempus Buys Personalis
Merck Oral PSCK9 OK’d, Vertex Snaps Up Crinetics, Lilly Buys a Psychedelic